Biotechnology company Alligator Bioscience AB (STO:ATORX) on Wednesday announced the publication of clinical data for its 4-1BB agonist, ATOR-1017, in the Journal for ImmunoTherapy of Cancer.
The data, from a first-in-human trial, demonstrates encouraging safety and tolerability in patients with advanced cancer.
The publication also highlights early signs of clinical efficacy, and pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism. These findings support the therapeutic potential of ATOR-1017, particularly in combination with other cancer therapies.
Alligator continues to prioritise the development of its lead candidate, mitazalimab, while exploring strategic options for advancing ATOR-1017.
RedHill Biopharma to submit Talicia for UK marketing authorisation
BiBBInstruments successfully demonstrates EndoDrill GI in live biopsy procedure
Telix Pharmaceuticals' Illuccix approved in Brazil
Physiomics secures GBP102,000 contract with UK biotech for ADC therapy development
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
iOncologi acquires TargImmune Therapeutics
Akeso's Penpulimab receives Chinese regulatory approval
BRAVO study confirms blue light cystoscopy reduces bladder cancer recurrence risk
Cantargia enrolls first patient in leukemia study with nadunolimab
OsteoCentric Technologies partners with Globus Medical to expand innovative implant technology
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
NeoGenomics acquires Pathline to strengthen Northeast oncology testing reach